Cargando…

Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor

No rodent models are currently available for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) without exogenous supplementation of tissue-type plasminogen activator (tPA). Characterization of tPA transgenic rats as a tool for the nonclinical evaluati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Yusuke, Noguchi, Kengo, Morishima, Yoshiyuki, Yamaguchi, Kyoji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943070/ https://www.ncbi.nlm.nih.gov/pubmed/29538006 http://dx.doi.org/10.1097/MBC.0000000000000723

Ejemplares similares

Generation and characterization of tissue-type plasminogen activator transgenic rats
por: Ito, Yusuke, et al.
Publicado: (2017)

Correction to: Generation and characterization of tissue-type plasminogen activator transgenic rats
por: Ito, Yusuke, et al.
Publicado: (2017)

Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis
por: Park, Rojin, et al.
Publicado: (2010)

Increased thrombin activatable fibrinolysis inhibitor activity is associated with hypofibrinolysis in dogs with sepsis
por: Sotos, Katherine E., et al.
Publicado: (2023)

Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review
por: Sillen, Machteld, et al.
Publicado: (2021)

Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI)
por: Valnickova, Zuzana, et al.
Publicado: (2009)

Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis
por: Bazzi, Zainab A., et al.
Publicado: (2016)

Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) activation in acquired hemostatic dysfunction: a diagnostic challenge
por: Kim, Hyun Kyung
Publicado: (2010)

Increased Thrombin-Activatable Fibrinolysis Inhibitor and Decreased Tissue Factor Pathway Inhibitor and Thrombomodulin Levels in Children with Hypothyroidism
por: Alioğlu, Bülent, et al.
Publicado: (2012)

Thrombin-activatable fibrinolysis inhibitor and organ dysfunction in disseminated intravascular coagulation associated with sepsis
por: Hayakawa, M, et al.
Publicado: (2011)

Data supporting the structural and functional characterization of Thrombin‐Activatable Fibrinolysis Inhibitor in breast cancer
por: Fawzy, Manal S., et al.
Publicado: (2015)

Thrombin-Activatable Fibrinolysis Inhibitor Polymorphisms and Cerebral Venous Thrombosis in Mexican Mestizo Patients
por: Arauz, Antonio, et al.
Publicado: (2018)

Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission
por: ERDOĞAN, Mehmet, et al.
Publicado: (2019)

Isolation, Co-Crystallization and Structure-Based Characterization of Anabaenopeptins as Highly Potent Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa)
por: Schreuder, Herman, et al.
Publicado: (2016)

Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke
por: Kraft, Peter, et al.
Publicado: (2010)

Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
por: Eser, Mehmet, et al.
Publicado: (2012)

Thrombin activatable fibrinolysis inhibitor as a bleeding predictor in liver transplantation: a pilot observational study
por: Nedel, Wagner Luis, et al.
Publicado: (2016)

A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor
por: Stanne, Tara M., et al.
Publicado: (2018)

Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study
por: Fawzy, Manal S., et al.
Publicado: (2015)

Dose-Response Relationship Between Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) and Stroke: A Chinese Case-Control Study
por: Dai, Huixu, et al.
Publicado: (2017)

A Case-Control Study of the Dose-Response Relationship Between Thrombin Activatable Fibrinolysis Inhibitor and Acute Myocardial Infarction
por: Zhao, Mengnan, et al.
Publicado: (2022)

Relationship Between Polymorphism of Thrombin-Activatable Fibrinolysis Inhibitor Gene +1040C/T and a Cohort of Chinese Women With Recurrent Spontaneous Abortion
por: Fang, Ping, et al.
Publicado: (2021)

Plasma thrombin-activatable fibrinolysis inhibitor and the 1040C/T polymorphism are risk factors for diabetic kidney disease in Chinese patients with type 2 diabetes
por: Huang, Qinghua, et al.
Publicado: (2023)

Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency
por: Saes, Joline L., et al.
Publicado: (2019)

Plasminogen activator inhibitor‐1 augments damage by impairing fibrinolysis after traumatic brain injury
por: Griemert, Eva‐Verena, et al.
Publicado: (2019)

Regulation of Chemerin Bioactivity by Plasma Carboxypeptidase N, Carboxypeptidase B (Activated Thrombin-activable Fibrinolysis Inhibitor), and Platelets
por: Du, Xiao-Yan, et al.
Publicado: (2009)

Plasminogen Receptors and Fibrinolysis
por: Miles, Lindsey A., et al.
Publicado: (2021)

Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats
por: Morishima, Yoshiyuki, et al.
Publicado: (2021)

Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2021)

Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix
Publicado: (1991)

SARS‐CoV‐2 infection results in upregulation of Plasminogen Activator Inhibitor‐1 and Neuroserpin in the lungs, and an increase in fibrinolysis inhibitors associated with disease severity
por: Toomer, Kevin H., et al.
Publicado: (2023)

Ixonnexin from Tick Saliva Promotes Fibrinolysis by Interacting with Plasminogen and Tissue-Type Plasminogen Activator, and Prevents Arterial Thrombosis
por: Assumpção, Teresa C., et al.
Publicado: (2018)

Commentary on “Elevated plasma levels of plasminogen activator inhibitor‐1 are associated with risk of future incident venous thromboembolism”: A new role for plasminogen activator inhibitor‐1—An inhibitor of fibrinolysis predicts future venous thromboembolic events and links them to obesity
por: Wojta, Johann
Publicado: (2022)

Ratiometric Activatable Cell-Penetrating Peptides Provide Rapid In Vivo Readout of Thrombin Activation**
por: Whitney, Michael, et al.
Publicado: (2013)

Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism
por: Stubblefield, William B., et al.
Publicado: (2016)

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Levels in Patients with Acute Paraquat Intoxication
por: Seok, Su-Jin, et al.
Publicado: (2011)

Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1
por: Gong, Lihu, et al.
Publicado: (2016)

Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in psychological stress and depression
por: Tsai, Shih-Jen
Publicado: (2017)

Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
por: Zuo, Yu, et al.
Publicado: (2021)

The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies
por: Longstaff, Colin, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_nal01mdiuqdbgq09garc6oct5q